Compare ELVA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVA | VSTM |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.7M | 395.4M |
| IPO Year | 2021 | 2011 |
| Metric | ELVA | VSTM |
|---|---|---|
| Price | $9.52 | $6.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $14.00 | ★ $16.50 |
| AVG Volume (30 Days) | 332.1K | ★ 3.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $34.68 | $282.64 |
| Revenue Next Year | $51.48 | $72.25 |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $3.66 | $3.43 |
| 52 Week High | $12.78 | $11.25 |
| Indicator | ELVA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 75.12 |
| Support Level | $8.96 | $5.53 |
| Resistance Level | $11.17 | $6.10 |
| Average True Range (ATR) | 0.89 | 0.43 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 38.97 | 97.19 |
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.